This page shows the latest Gocovri news and features for those working in and with pharma, biotech and healthcare.
In two phase 3 clinical studies, Gocovri treatment was shown to significantly reduce both OFF time and dyskinesia. ... Gocovri is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,”
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...